Drug development for CNS disorders: strategies for balancing risk and reducing attrition (Q36864041)

16 August 2017

1 reference

title

Drug development for CNS disorders: strategies for balancing risk and reducing attrition (English)

1 reference

16 August 2017

Menelas N Pangalos

1 reference

16 August 2017

Lee E Schechter

series ordinal

1 reference

16 August 2017

Orest Hurko

series ordinal

1 reference

16 August 2017

publication date

1 July 2007

1 reference

Nature Reviews Drug Discovery

16 August 2017

published in

1 reference

16 August 2017

1 reference

16 August 2017

1 reference

16 August 2017

page(s)

521-532

1 reference

CT contrast enhancement on brain scans and blood-CSF barrier disturbances in cerebral ischemic infarction

16 August 2017

cites work

1 reference

Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease

21 January 2018

1 reference

Recommendations for standards regarding preclinical neuroprotective and restorative drug development

21 January 2018

1 reference

Protein-tyrosine kinases and adaptor proteins in FcepsilonRI-mediated signaling in mast cells

21 January 2018

1 reference

Sensorimotor gating and schizophrenia. Human and animal model studies

21 January 2018

1 reference

Impact of genomics on drug discovery and clinical medicine.

21 January 2018

1 reference

Global prevalence of dementia: a Delphi consensus study

21 January 2018

1 reference

Can the pharmaceutical industry reduce attrition rates?

31 March 2020

1 reference

Arterial hypertension and stroke prevention: an update

31 March 2020

1 reference

Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection

31 March 2020

1 reference

Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors

31 March 2020

1 reference

Disease modifying strategies for the treatment of Alzheimer's disease targeted at modulating levels of the beta-amyloid peptide

31 March 2020

1 reference

Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease

31 March 2020

1 reference

Characterization of the reconstituted gamma-secretase complex from Sf9 cells co-expressing presenilin 1, nicastrin [correction of nacastrin], aph-1a, and pen-2.

31 March 2020

1 reference

A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions

31 March 2020

1 reference

BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics

31 March 2020

1 reference

Crystal structure of memapsin 2 (beta-secretase) in complex with an inhibitor OM00-3

31 March 2020

1 reference

Prospects for productivity

31 March 2020

1 reference

Dendritic plasticity in the adult rat following middle cerebral artery occlusion and Nogo-a neutralization

31 March 2020

1 reference

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

31 March 2020

1 reference

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

31 March 2020

1 reference

Neuropathological stageing of Alzheimer-related changes

31 March 2020

1 reference

Inflammation and Alzheimer's disease

31 March 2020

1 reference

Are mitochondria critical in the pathogenesis of Alzheimer's disease?

31 March 2020

1 reference

Identification of Src-specific phosphorylation site on focal adhesion kinase: dissection of the role of Src SH2 and catalytic functions and their consequences for tumor cell behavior

31 March 2020

1 reference

Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke

31 March 2020

1 reference

Diabetes: assessing the pipeline

31 March 2020

1 reference

Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis

31 March 2020

1 reference

Role for peroxisome proliferator-activated receptor-gamma in Alzheimer's disease.

31 March 2020

1 reference

Antiobesity-like effects of the 5-HT2C receptor agonist WAY-161503.

31 March 2020

1 reference

Innovative approaches for the development of antidepressant drugs: current and future strategies

31 March 2020

1 reference

Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity

31 March 2020

1 reference

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

31 March 2020

1 reference

NXY-059 for acute ischemic stroke

31 March 2020

1 reference

NXY-059: review of neuroprotective potential for acute stroke

31 March 2020

1 reference

31 March 2020

1 reference

Longitudinal stability of MRI for mapping brain change using tensor-based morphometry

31 March 2020

1 reference

The potential utility of transgenic mice harboring beta-amyloid precursor protein

31 March 2020

1 reference

Mouse models of human neurodegenerative disorders: requirements for medication development

31 March 2020

1 reference

BACE1 (beta-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes

31 March 2020

1 reference

BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions.

31 March 2020

1 reference

The history of the psychopharmacology of schizophrenia

31 March 2020

1 reference

Climbing behaviour induced by apomorphine in mice: A potential model for the detection of neuroleptic activity

31 March 2020

1 reference

To model a psychiatric disorder in animals: schizophrenia as a reality test

31 March 2020

1 reference

Assessing antidepressant activity in rodents: recent developments and future needs

31 March 2020

1 reference

Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists

31 March 2020

1 reference

Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential

31 March 2020

1 reference

Clinical biomarkers in drug discovery and development

31 March 2020

1 reference

Preclinical models: status of basic research in depression

31 March 2020

1 reference

A manic depressive history.

31 March 2020

1 reference

On the resolution and feasibility of genome scanning approaches

31 March 2020

1 reference

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

31 March 2020

1 reference

A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development

31 March 2020

1 reference

Cutting the cost of drug development?

31 March 2020

1 reference

Learning versus confirming in clinical drug development

31 March 2020

1 reference

Cognitive reserve and the neurobiology of cognitive aging

31 March 2020

1 reference

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

31 March 2020

1 reference

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

31 March 2020

1 reference

Medication augmentation after the failure of SSRIs for depression.

31 March 2020

1 reference

Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects

31 March 2020

1 reference

Drug interactions with cholinesterase inhibitors

31 March 2020

1 reference

Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine

31 March 2020

1 reference

Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene

31 March 2020

1 reference

Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).

31 March 2020

1 reference

Positron Emission Tomography and Drug Discovery Contributions to the Understanding of Pharmacokinetics, Mechanism of Action and Disease State Characterization

31 March 2020

1 reference

A comparative assessment of the efficacy and side-effect liability of neuroprotective compounds in experimental stroke

31 March 2020

1 reference

An Abeta sequestration approach using non-antibody Abeta binding agents

31 March 2020

1 reference

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

31 March 2020

1 reference

Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

31 March 2020

1 reference

Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer's disease: original data and review of the literature

31 March 2020

1 reference

Lipid peroxidation and oxidative imbalance: early functional events in Alzheimer's disease.

31 March 2020

1 reference

Low Baseline Bispectral Index of the Electroencephalogram in Patients with Dementia

31 March 2020

1 reference

Role of the bispectral index in sedation monitoring in the ICU.

31 March 2020

1 reference

Human EEG gamma oscillations in neuropsychiatric disorders.

31 March 2020

1 reference

Human spatial navigation deficits after traumatic brain injury shown in the arena maze, a virtual Morris water maze.

31 March 2020

1 reference

Alzheimer's patients engage an alternative network during a memory task.

31 March 2020

1 reference

Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease

31 March 2020

1 reference

Binding of the positron emission tomography tracer Pittsburgh compound-B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain.

31 March 2020

1 reference

Development and evaluation of iodinated tracers targeting amyloid plaques for SPECT imaging

31 March 2020

1 reference

Assessment of neuroinflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study

31 March 2020

1 reference

Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience

31 March 2020

1 reference

fMRI of lexical-semantic priming in a chronic schizophrenia patient

31 March 2020

1 reference

Dopaminergic modulation of visual attention and working memory in the rodent prefrontal cortex

31 March 2020

1 reference

Performance of the marmoset monkey on computerized tasks of attention and working memory.

31 March 2020

1 reference

Effects of the mGluR2/3 agonist LY354740 on computerized tasks of attention and working memory in marmoset monkeys

31 March 2020

1 reference

Concordance of the toxicity of pharmaceuticals in humans and in animals

31 March 2020

1 reference

Gene expression profiling for pharmaceutical safety assessment

31 March 2020

1 reference

31 March 2020

1 reference

Risk factors associated with beta-amyloid(1-42) immunotherapy in preimmunization gene expression patterns of blood cells.

31 March 2020

1 reference

Selective loss of central cholinergic neurons in Alzheimer's disease

31 March 2020

1 reference

Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies

31 March 2020

1 reference

Necropsy evidence of central cholinergic deficits in senile dementia

31 March 2020

1 reference

Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain

31 March 2020

1 reference

The cholinergic hypothesis of geriatric memory dysfunction

31 March 2020

1 reference

Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry

31 March 2020

1 reference

Antemortem measurements of neurotransmission: possible implications for pharmacotherapy of Alzheimer's disease and depression

31 March 2020

1 reference

Lecozotan (SRA-333): a selective serotonin 1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and possesses cognitive-enhancing properties.

31 March 2020

1 reference

5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation--an effect sensitive to NMDA receptor antagonism

31 March 2020

1 reference

H3 receptor blockade by thioperamide enhances cognition in rats without inducing locomotor sensitization

31 March 2020

1 reference

Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics

31 March 2020

1 reference

Molecular biology and genetics of Alzheimer's disease

31 March 2020

1 reference

Gene dosage of the amyloid beta precursor protein in Alzheimer's disease

31 March 2020

1 reference

ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo

31 March 2020

1 reference

Abeta toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets

31 March 2020

1 reference

A specific amyloid-beta protein assembly in the brain impairs memory

31 March 2020

1 reference

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

31 March 2020

1 reference

Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer's disease

31 March 2020

1 reference

Demonstration of extraneuronal 5-hydroxytryptamine accumulation in brain following membrane-pump blockade by chlorimipramine

31 March 2020

1 reference

Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists.

31 March 2020

1 reference

Will the genomics revolution revolutionize psychiatry?

31 March 2020

1 reference

Discovering endophenotypes for major depression

31 March 2020

1 reference

Season of birth and obstetrical complications in schizophrenics

31 March 2020

1 reference

Craniofacial dysmorphology in Swedish schizophrenia patients

31 March 2020

1 reference

Untreated Depression and Hippocampal Volume Loss

31 March 2020

1 reference

Hippocampal atrophy in recurrent major depression

31 March 2020

1 reference

Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus

31 March 2020

1 reference

Classical conditioning in patients with Alzheimer's disease: a multiday study.

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRD2094

1 reference

16 August 2017

1 reference